ABSTRACT
Streptococcus oralis an opportunistic bacterium has been reported to be involved in various blood borne infections like subacute bacterial endocarditis, septicemia, bacterial meningitis and in some cases dental caries too. Among various targets the peptide deformylase, of S.oralis appears to be most potent druggable target as it is involved in protein synthesis is opted for the current study. Due to unavailability of PDB structure of peptide deformylase from S. oralis the study initiates with homology modelling of the protein and 6OW2 of S pneumoniae is considered as the template. Thereafter, Molecular docking, Molecular dynamic simulation, ADME analysis, and MMPBSA analysis was carried out to explore the inhibitory potential of phyto-constituents as potential inhibitors for Peptide deformylase from S.oralis. Actinonin was considered as reference drug. Among 2370 phyto compounds the best observations were recorded for A1-Barrigenol (IMPHY010984) with binding affinity of -8.5 kcal/mol. Calculated RMSD, RMSF, Binding Free Energy for IMPHY010984 averaged at about 0.10 ± 0.03 nm, 0.08 ± 0.05 nm, 131 ± 21 kJ/mol respectively whereas the RMSD, RMSF, Binding Free Energy recorded for reference drug averaged at about 0.19 ± 0.04 nm, 0.11 ± 0.08 nm, -94 ± 18 kJ/mol respectively. Based on in silico observations IMPHY010984 is proved out as superior candidate over reference drug. The study reflects the potential of IMPHY010984 as prophylactic therapeutics for S.oralis.
Subject(s)
Amidohydrolases , Molecular Docking Simulation , Molecular Dynamics Simulation , Streptococcus oralis , Amidohydrolases/antagonists & inhibitors , Amidohydrolases/metabolism , Amidohydrolases/chemistry , Streptococcus oralis/enzymology , Streptococcus oralis/drug effects , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/chemistry , Phytochemicals/chemistry , Phytochemicals/pharmacology , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Bacterial Proteins/chemistry , Hydroxamic AcidsABSTRACT
BACKGROUND: Early colonizers adhere to the dental surface and facilitate the initial adhesion of secondary colonizers to form oral biofilms, which may cause oral infections. OBJECTIVES: This study aimed to determine the antimicrobial, anti-adhesion and antibiofilm potency of inverted amino acids on early colonizer streptococci and their mixed species. MATERIAL AND METHODS: The following test strains were used: Streptococcus gordonii (American Type Culture Collection (ATCC) 35105); Streptococcus mitis (ATCC 49456); Streptococcus oralis (ATCC 10557); Streptococcus salivarius (ATCC 7073); and Streptococcus sanguinis (ATCC BAA-1455). The concentration-dependent antimicrobial potency of d-alanine (d-ala), d-arginine (d-arg), d-leucine (d-leu), d-methionine (d-met), and d-tryptophan (d-try) was determined using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method with AlamarBlue modification. The adhesion of primary colonizers in the presence of 25-mM d-amino acids (dAAs) was assessed using the colony forming unit (CFU) assay. The CFU assay was conducted on 24-h flow cell bacterial biofilm models after exposure to 25-mM inverted dAAs. RESULTS: No minimum inhibitory concentration (MIC) point was detected at any concentration tested. The minimum bactericidal concentration (MBC) point was not observed. The adhesion of S. mitis, S. oralis and mixed species was reduced by all tested dAAs. No adverse effects were observed on S. gordonii with any of the tested dAAs. The biofilm biomass of test strains under flow conditions was significantly reduced after a 5-min exposure to all tested dAAs at 25-mM concentration. CONCLUSIONS: D-amino acids did not inhibit bacterial growth and did not show bactericidal or bacteriostatic effects on test strains at any concentration tested (ranging from 6.25 mM to 100 mM). However, dAAs effectively inhibit the adhesion of early colonizers, thereby preventing the formation of oral biofilm.
Subject(s)
Amino Acids , Bacterial Adhesion , Biofilms , Streptococcus , Biofilms/drug effects , Bacterial Adhesion/drug effects , Amino Acids/pharmacology , Amino Acids/administration & dosage , Streptococcus/drug effects , Microbial Sensitivity Tests , Humans , Biomass , Arginine/pharmacology , Streptococcus gordonii/drug effects , Anti-Bacterial Agents/pharmacology , Streptococcus oralis/drug effects , Leucine/pharmacology , Tryptophan/pharmacologyABSTRACT
This study aimed to evaluate the antimicrobial effect of Thymoquinone (TQ) on four different oral microorganisms. Minimum Bactericidal Concentration (MBC), Minimum Inhibition Concentration (MIC), Broth microdilution, and Well diffusion tests were used to determine the optimum antimicrobial concentrations of TQ against Streptococcus salivarius, Streptococcus oralis, Streptococcus mutans, and Staphylococcus aureus over 1, 3, 6, 12 and 24 h. Chlorhexidine 0.12% was selected as a positive control. The inhibitory effect of TQ on bacterial growth was most noticeable with S. salivarius, while the least affected was S. aureus. TQ's MBC and MIC for S. oralis and S. aureus were comparable 2 mg/mL and 3 mg/mL, respectively. S. salivarius was most resistant to TQ and displayed a value of 5 mg/mL and 4 mg/mL for MIC and MBC, respectively. The viable count of different strains after exposure to TQ's MBC values was most noticeable with S. aureus followed by S. oralis and S. mutans, while S. salivarius was least affected. This study emphasized the promising antimicrobial effect of TQ against the four main oral microorganisms. It has a potential preventive effect against dental caries as well as other oral diseases.
Subject(s)
Anti-Bacterial Agents/pharmacology , Benzoquinones/pharmacology , Staphylococcus aureus/drug effects , Streptococcus mutans/drug effects , Streptococcus oralis/drug effects , Streptococcus salivarius/drug effects , Anti-Bacterial Agents/chemistry , Benzoquinones/chemistry , Microbial Sensitivity TestsABSTRACT
PURPOSE: During cancer treatment, oral mucositis due to radiotherapy or chemotherapy often leads to disruption of the oral mucosa, enabling microbes to invade bloodstream. Viridans streptococcal species are part of the healthy oral microbiota but can be frequently isolated from the blood of neutropenic patients. We have previously shown the antibacterial efficacy of dual-light, the combination of antibacterial blue light (aBL) and indocyanine green photodynamic therapy (aPDT). METHODS: Here, we investigated the dual-light antibacterial action against four-day Streptococcus oralis biofilm. In addition, while keeping the total radiant exposure constant at 100J/cm2, we investigated the effect of changing the different relative light energies of aBL and aPDT to the antibacterial potential. RESULTS: The dual-light had a significant antibacterial effect in all the tested combinations. CONCLUSION: Dual-light can be used as an effective disinfectant against S. oralis biofilm.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Biofilms/drug effects , Indocyanine Green/therapeutic use , Photochemotherapy/methods , Streptococcus oralis/drug effects , Humans , Stomatitis/drug therapy , Stomatitis/microbiology , Streptococcal Infections/drug therapy , Streptococcal Infections/microbiologyABSTRACT
Dental plaque is a biofilm composed of a complex oral microbial community. The accumulation of plaque in the pit and fissures of dental elements often leads to the development of tooth decay (dental caries). Here, potent anti-biofilm materials were developed by incorporating zinc methacrylates or di-n-butyl-dimethacrylate-tin into the light-curable sealant and their physical, mechanical, and biological properties were evaluated. The data revealed that 5% di-n-butyl-dimethacrylate-tin (SnM 5%) incorporated sealant showed strong anti-biofilm efficacy against various single-species (Streptococcus mutans or Streptococcus oralis or Candida albicans) and S. mutans-C. albicans cross-kingdom dual-species biofilms without either impairing the mechanical properties of the sealant or causing cytotoxicities against mouse fibroblasts. The findings indicate that the incorporation of SnM 5% in the experimental pit and fissure self-adhesive sealant may have the potential to be part of current chemotherapeutic strategies to prevent the formation of cariogenic oral biofilms that cause dental caries.
Subject(s)
Adhesives/pharmacology , Biofilms/drug effects , Dental Caries/prevention & control , Pit and Fissure Sealants/pharmacology , Zinc/chemistry , Adhesives/chemistry , Animals , Biofilms/growth & development , Candida albicans/drug effects , Candida albicans/growth & development , Dental Caries/microbiology , Humans , Methacrylates/chemistry , Mice , Microbiota/drug effects , Pit and Fissure Sealants/chemistry , Streptococcus mutans/drug effects , Streptococcus mutans/growth & development , Streptococcus oralis/drug effects , Streptococcus oralis/growth & developmentABSTRACT
Streptococcus oralis is an early colonizer bacterium in dental plaques and is considered a potential pathogen of infective endocarditis (IE) disease. In this study, we built a complete genome map of Streptococcus oralis strain SOT, Streptococcus oralis strain SOD and Streptococcus infantis strain SO and performed comparative genomic analysis among these three strains. The results showed that there are five genomic islands (GIs) in strain SOT and one CRISPR in strain SOD. Each genome harbors various pathogenic genes related to diseases and drug resistance, while the antibiotic resistance genes in strains SOT and SOD were quite similar but different from those in strain SO. In addition, we identified 17 main virulence factors and capsule-related genes in three strains. These results suggest the pathogenic potential of Streptococcus strains, which lay a foundation for the prevention and treatment of a Streptococcus oralis infection.
Subject(s)
Comparative Genomic Hybridization , Drug Resistance, Bacterial/genetics , Genes, Bacterial , Streptococcus oralis/genetics , Anti-Bacterial Agents/pharmacology , RNA, Ribosomal, 16S/genetics , Streptococcus oralis/drug effects , Virulence Factors/geneticsABSTRACT
Following antimicrobial administrations in oral environments, bacteria become exposed to a sub-minimum inhibitory concentration (sub-MIC), which can induce in vitro single-species biofilms. This study explored the effects of chlorhexidine gluconate (CHG) at a sub-MIC on in vitro multi-species biofilms comprising Streptococcus mutans, Streptococcus oralis and Actinomyces naeslundii. CHG at a sub-MIC was found to induce in vitro biofilm growth, although the bacterial growth was not significantly different from that in the control. The gene transcription related to S. mutans multi-species biofilm formation with CHG at a sub-MIC was significantly higher than that of the control, but this was not found in S. mutans single-species biofilms. The bio-volume of extracellular polysaccharides with CHG at a sub-MIC was significantly higher than that of the control. This suggests that CHG at a sub-MIC may promote the development of multi-species biofilms by affecting the gene transcription related to S. mutans biofilm formation.
Subject(s)
Actinomyces/drug effects , Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Chlorhexidine/analogs & derivatives , Streptococcus mutans/drug effects , Streptococcus oralis/drug effects , Actinomyces/genetics , Biofilms/growth & development , Chlorhexidine/pharmacology , Dose-Response Relationship, Drug , Microbial Sensitivity Tests , Streptococcus mutans/genetics , Streptococcus oralis/genetics , Transcriptome/drug effectsABSTRACT
We reported the case of a patient with leukemia who developed febrile neutropenia after hematopoietic stem cell transplantation. Blood culture results revealed the presence of Streptococcus oralis, while antimicrobial susceptibility testing showed the resistance to penicillin and cephem. Furthermore, isolates were not susceptible to either meropenem or daptomycin but not to vancomycin. S oralis is known to belong to Streptococcus mitis group and be a causative agent of bacteremia in the neutropenic patients, but multidrug resistance of S oralis is rare. Our findings suggest that we might pay attention to the emergence of the microorganisms acquiring multidrug resistance in neutropenic patients.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia/diagnosis , Drug Resistance, Multiple, Bacterial , Febrile Neutropenia/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Streptococcal Infections/diagnosis , Adult , Bacteremia/drug therapy , Febrile Neutropenia/microbiology , Female , Humans , Leukemia/therapy , Microbial Sensitivity Tests , Streptococcal Infections/drug therapy , Streptococcus oralis/drug effects , Treatment OutcomeABSTRACT
Biofilms are matrices synthesized by bacteria containing polysaccharides, DNA, and proteins. The development of biofilms in infectious processes can induce a chronic inflammatory response that may progress to the destruction of tissues. The treatment of biofilms is difficult because they serve as a bacterial mechanism of defense and high doses of antibiotics are necessary to treat these infections with limited positive results. It has been demonstrated that photothermal therapy using gold nanorods (AuNRs) is an attractive treatment because of its anti-biofilm activity. The purpose of this work was to generate a novel chitosan-based hydrogel embedded with AuNRs to evaluate its anti-biofilm activity. AuNRs were synthesized by the seed-mediated growth method and mixed with the chitosan-based hydrogel. Hydrogels were characterized and tested against two bacterial strains by irradiating the produced biofilm in the presence of the nanoformulation with a laser adjusted at the near infrared spectrum. In addition, the safety of the nanoformulation was assessed with normal human gingival fibroblasts. Results showed that a significant bacterial killing was measured when biofilms were exposed to an increase of 10°C for a short time of 2 min. Moreover, no cytotoxicity was measured when normal gingival fibroblasts were exposed to the nanoformulation using the bactericidal conditions. The development of the reported formulation can be used as a direct application to treat periodontal diseases or biofilm-produced bacteria that colonize the oral cavity.
Subject(s)
Anti-Bacterial Agents/chemistry , Biofilms/drug effects , Chitosan/chemistry , Gold/chemistry , Hydrogels/chemistry , Nanotubes/chemistry , Photosensitizing Agents/chemistry , Anti-Bacterial Agents/pharmacology , Cell Survival/drug effects , Disinfection , Drug Compounding , Enterococcus faecalis/drug effects , Fibroblasts/cytology , Gingiva/cytology , Gold/pharmacology , Hot Temperature , Humans , Infrared Rays , Lasers , Microbial Viability/drug effects , Photosensitizing Agents/pharmacology , Photothermal Therapy , Streptococcus oralis/drug effectsABSTRACT
In this study, the chemical composition, genotoxic, cytotoxic and antibacterial-modulating activities of the P. pyramidalis (NPpE) extract was evaluated. The fingerprint chromatogram was determined using HPLC-DAD. The NPpE Minimal Inhibitory Concentration (MIC), as well as that of antimicrobial drugs in the presence and absence of the extract, were evaluated using the microdilution method against Gram positive bacteria. In vivo assays with mice were used for the determination of the extract's genotoxicity and cytotoxicity. The presence of the polyphenol catechin was confirmed in the extract. The extract showed significant antimicrobial activity (MIC ≤ 1000 µg mL-1) against Staphylococcus aureus, Streptococcus oralis and S. mutans. When the NPpE was associated with several antimicrobials, the MIC of most of these were significantly reduced (P < 0.001) demonstrating good prospective usage in antimicrobial therapy. The extract has mutagenic and cytotoxic potential, however, further studies should be performed to confirm their toxicity.
Subject(s)
Anti-Bacterial Agents/pharmacology , Fabaceae/chemistry , Phytochemicals/pharmacology , Animals , Anti-Bacterial Agents/chemistry , Catechin/pharmacology , Chromatography, High Pressure Liquid , Drug Evaluation, Preclinical , Mice , Microbial Sensitivity Tests , Mutagenicity Tests , Phytochemicals/analysis , Phytochemicals/chemistry , Phytochemicals/toxicity , Plant Extracts/chemistry , Plant Extracts/pharmacology , Polyphenols/analysis , Staphylococcus aureus/drug effects , Streptococcus oralis/drug effectsABSTRACT
Streptococcus oralis subspecies dentisani is explored as an anti-cariogenic probiotic. Here, subjecting freshly stimulated saliva samples of 35 healthy volunteers, six epidemiologically unrelated and two related strains were isolated (prevalence around 20%) applying a newly developed three-step procedure. Furthermore, the probiotic strain S. dentisani 7746 (AB-Dentisanium®) was tested under a variety of environmental conditions for its inhibitory effect on six S. mutans, two S. sobrinus, 15 other oral or intestinal streptococci, 15 S. dentisani strains, and six representatives of other species including periodontopathogens. All except one of the S. mutans strains were inhibited by 7746 colonies or culture supernatant concentrate but only if either the test cell number was low or the producer or its bacteriocin concentration, respectively, was high. S. sanguinis OMI 332, S. salivarius OMI 315, S. parasanguinis OMI 335, S. vestibularis OMI 238, and the intestinal S. dysgalactiae OMI 339 were not inhibited, while the other 10 streptococcal strains (especially S. oralis OMI 334 and intestinal S. gallolyticus OMI 326) showed a certain degree of inhibition. From the panel of other bacterial species only Aggregatibacter actinomycetemcomitans was slightly inhibited. With the exception of OMI 285 and OMI 291 that possessed a 7746 bacteriocin-like gene cluster, all S. dentisani strains and especially type strain 7747T were strongly inhibited by 7746. In conclusion, probiotic strain 7746 might antagonize the initiation and progression of dental caries by reducing S. mutans if not too abundant. S. dentisani strains inhibit each other, but strains with similar bacteriocin-related gene clusters, including immunity genes, are able to co-exist due to cross-resistance. In addition, development of resistance and adaptation to 7746-bacteriocins was observed during our study and needs attention. Hence, mechanisms underlying such processes need to be further investigated using omics-approaches. On the manufacturing level, probiotic strains should be continuously tested for function. Further clinical studies investigating inhibition of S. mutans by AB-Dentisanium® are required that should also monitor the impact on the oral microbiome composition including resident S. dentisani strains.
Subject(s)
Anti-Bacterial Agents/metabolism , Bacterial Typing Techniques/methods , Bacteriocins/metabolism , Probiotics/isolation & purification , Streptococcal Infections/microbiology , Streptococcus oralis/classification , Streptococcus oralis/isolation & purification , Aggregatibacter actinomycetemcomitans/drug effects , Antibiosis , Carrier State/epidemiology , Carrier State/microbiology , Healthy Volunteers , Prevalence , Streptococcal Infections/epidemiology , Streptococcus mutans/growth & development , Streptococcus oralis/drug effects , Streptococcus sobrinus/growth & developmentABSTRACT
The viridans group streptococci (VGS) are a heterogeneous group of organisms which are important components of the normal human oral flora. Among the VGS, the Streptococcus mitis/oralis subgroup is one of the most common causes of infective endocarditis (IE). Daptomycin (DAP) is a potential alternative therapeutic option for invasive S. mitis infections, given high rates of ß-lactam resistance and vancomycin tolerance in such strains. However, the ability of these strains to rapidly evolve high-level and durable DAP resistance (DAP-R) is problematic. Recent data suggest that combination DAP-ß-lactam therapy circumvents this issue. Human-simulated dose-escalating DAP-alone dose regimens (6, 8, 10, or 12 mg/kg/day times 4 days) versus DAP (6 mg/kg/day) plus ceftriaxone (CRO) (2 g once daily times 4 days or 0.5 g, single dose) were assessed against two prototypical DAP-susceptible (DAP-S) S. mitis/oralis strains (SF100 and 351), as measured by a pharmacokinetic/pharmacodynamic (PK/PD) model of simulated endocardial vegetations (SEVs). No DAP-alone regimen was effective, with regrowth of high-level DAP-R isolates observed for both strains over 96-h exposures. Combinations of DAP-CRO with either single- or multidose regimens yielded significant reductions in log10 CFU/g amounts within SEVs for both strains (â¼6 log10 CFU/g) within 24 h. In addition, no DAP-R strains were detected in either DAP-CRO combination regimens over the 96-h exposure. In contrast to prior in vitro studies, no perturbations in two key cardiolipin biosynthetic genes (cdsA and pgsA) were identified in DAP-R SEV isolates emerging from strain 351, despite defective phospholipid production. The combination of DAP-CRO warrants further investigation for treatment of IE due to S. mitis/oralis.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Ceftriaxone/administration & dosage , Daptomycin/administration & dosage , Endocarditis, Bacterial/drug therapy , Streptococcus mitis/drug effects , Streptococcus oralis/drug effects , Drug Resistance, Bacterial/drug effects , Drug Therapy, Combination/methods , Endocarditis/drug therapy , Endocarditis/microbiology , Endocarditis, Bacterial/microbiology , Humans , Microbial Sensitivity Tests/methods , Streptococcus mitis/metabolism , Streptococcus oralis/metabolism , Vancomycin/administration & dosage , beta-Lactams/metabolismABSTRACT
Introducción: El objetivo de este estudio consiste en evaluar la eficacia clínica y microbiológica de un colutorio a base de digluconato de clorhexidina (CHX) 0,05% y cloruro de cetilpiridinio (CPC) 0,05%, y otro colutorio sin propiedades antisépticas, empleados como coadyuvantes de los métodos de higiene oral. Material y métodos: Se llevó a cabo un estudio microbiológico que evaluó la capacidad de los colutorios para inhibir la formación y adherencia de un biofilm bacteriano de Streptococcus oralis mediante espectrofotometría, y un ensayo clínico, aleatorizado y doble ciego sobre una muestra de 48 pacientes, los cuales fueron asignados aleatoriamente a cada colutorio. A: CHX 0,05%, CPC 0,05% y lactato de cinc 0,14% y B: permethol 0.10% y provitamina B5 0.50%. El índice de placa (IP), el índice gingival modificado (IGM) y el índice de sangrado (IS) fueron evaluados con periodicidad mensual y trimestral. Resultados: El colutorio a base de CHX 0,05% y CPC 0,05% evidenció una elevada capacidad para inhibir la formación (P=0,013) y adherencia (P=0,001) del biofilm bacteriano Se observaron diferencias estadísticamente significativas en el IP inter-grupos a los tres meses de observación (P<0,001). También se observaron diferencias en el IGM al mes (P=0,034) y a los tres meses de observación (P<0,001); y en el IS al mes (P=0,004) y a los tres meses de observación (P=0,002). Conclusiones: El colutorio a base de CHX 0,05% y CPC 0,05% posee una capacidad superior para reducir la placa bacteriana y la gingivitis
Introduction: The aim of this study was to evaluate the clinical and microbiological efficacy of a mouthrinse containing 0.05% chlorhexidine digluconate (CHX) and 0.05% cetylpyridinium chloride (CPC), and another mouthrinse without antiseptic properties, used as adjuvants to oral hygiene methods. Material and methods: First a microbiological study using spectrophotometry was done to assess the ability of both mouthrinses to inhibit the formation and adhesion of an Streptococcus oralis biofilm. Then, a randomised, double-blind clinical trial was performed on a sample of 48 patients, who were randomly assigned to each mouthrinse. A: 0.05% CHX and 0.05% CPC, and B: 0.10% permethol and 0.50% provitamin B5. Plaque index (PI), modified gingival index (MGI) and bleeding index (BI) were assessed at one and three months. Results: The 0.05% CHX and 0.05% CPC mouthrinse showed a high capacity to inhibit the formation (P=0.013) and adhesion (P=0.001) of the bacterial biofilm. Statistically significant differences were observed in the inter-group PI after three months of monitoring (P<0.001). Differences were also observed in MGI after one month (P=0,034) and after three months of monitoring (P<0,001); and in BI after one month (P=0,004) and after three months of monitoring (P=0,002). Conclusions: The 0.05% CHX and 0.05% CPC mouthrinse has a good capacity to reduce bacterial plaque and gingivitis
Subject(s)
Humans , Male , Female , Young Adult , Adult , Middle Aged , Mouthwashes/administration & dosage , Mouthwashes/pharmacology , Chlorhexidine/administration & dosage , Chlorhexidine/pharmacology , Cetylpyridinium/administration & dosage , Cetylpyridinium/pharmacology , Streptococcus oralis/drug effects , Streptococcal Infections/drug therapy , Dental Plaque/drug therapy , Dental Plaque/microbiology , Prospective Studies , Spectrophotometry , Double-Blind Method , Treatment OutcomeABSTRACT
We investigated the ability of several recent clinical viridans group streptococci (VGS) bloodstream isolates (Streptococcus mitis/S. oralis subgroup) from daptomycin (DAP)-naive patients to develop DAP resistance in vitro All strains rapidly developed high-level and stable DAP resistance. Substitutions in two enzymes involved in the cardiolipin biosynthesis pathway were identified, i.e., CdsA (phosphatidate cytidylyltransferase) and PgsA (CDP-diacylglycerol-glycerol-3-phosphate-3-phosphatidyltransferase). These mutations were associated with complete disappearance of phosphatidylglycerol and cardiolipin from cell membranes. DAP interactions with the cell membrane differed in isolates with PgsA versus CdsA substitutions.
Subject(s)
Anti-Bacterial Agents/pharmacology , Daptomycin/pharmacology , Nucleotidyltransferases/genetics , Streptococcus mitis/genetics , Streptococcus oralis/genetics , Transferases (Other Substituted Phosphate Groups)/genetics , Cardiolipins/metabolism , Cell Membrane/genetics , Cell Membrane/metabolism , Drug Resistance, Bacterial/genetics , Humans , Microbial Sensitivity Tests , Phosphatidylglycerols/metabolism , Streptococcus mitis/drug effects , Streptococcus mitis/isolation & purification , Streptococcus oralis/drug effects , Streptococcus oralis/isolation & purificationSubject(s)
Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , Cephalosporins/pharmacology , Registries/statistics & numerical data , Streptococcus mitis/drug effects , Streptococcus oralis/drug effects , beta-Lactam Resistance , Humans , Microbial Sensitivity Tests , Netherlands/epidemiology , Prevalence , Streptococcal Infections/epidemiology , Streptococcal Infections/microbiology , Streptococcus mitis/isolation & purification , Streptococcus oralis/isolation & purificationABSTRACT
Viridans streptococci are still under investigation concerning epidemiology, pathogenesis and clinical presentations. We aimed to investigate the clinical presentations and outcomes of pediatric patients infected with Streptococcus mitis/oralis. Based on the accumulation of bloodstream infections (BSI) caused by S. mitis/oralis in 4 patients in our Hematology and Bone Marrow Transplantation Department at a particular time, a review of the medical and microbiological records of pediatric patients with positive blood cultures for S. mitis/oralis in the entire hospital was performed. In addition, a retrospective case-control study was conducted. Pulsed-field gel electrophoresis of S. mitis/oralis in 4 patients displayed unrelatedness of the strains. A total of 53 BSI (42 BSI and 11 catheter-related BSI) were analyzed. Thirty-four percent of patients with BSI caused by S. mitis/oralis had febrile neutropenia. Clinical and microbiological outcomes were favorable and infection-related mortality was not observed. Although not significant, previous antibiotic use and trimethoprim-sulfamethoxazole prophylaxis were more common in the case group. S. mitis/oralis seems likely an important agent in bacteremic children who are particularly neutropenic because of the underlying hematologic and oncologic diseases. Prompt management of infections with appropriate antimicrobials, regarding antibiotic susceptibilities of organisms, may facilitate favorable outcomes.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Bacteremia/diagnosis , Streptococcal Infections/diagnosis , Streptococcal Infections/microbiology , Streptococcus mitis , Streptococcus oralis , Adolescent , Anti-Bacterial Agents/pharmacology , Bacteremia/drug therapy , Bacteremia/microbiology , Case-Control Studies , Catheter-Related Infections/diagnosis , Catheter-Related Infections/drug therapy , Catheter-Related Infections/microbiology , Child , Child, Preschool , Female , Hematologic Diseases/complications , Humans , Infant , Male , Microbial Sensitivity Tests , Retrospective Studies , Streptococcal Infections/drug therapy , Streptococcus mitis/drug effects , Streptococcus oralis/drug effects , Treatment OutcomeABSTRACT
The extracellular polymer substances (EPS) generated by biofilms confers resistance to antimicrobial agents through electrostatic and steric interactions that hinder molecular diffusion. This resistance mechanism is particularly evident for antibacterial nanomaterials, which inherently diffuse more slowly compared to small organic antibacterial agents. The aim of this study was to determine if a biofilm's resistance to antibacterial nanomaterial diffusion could be diminished using electrolytes to screen the EPS's electrostatic interactions. Anionic (+) alpha-tocopherol phosphate (α-TP) liposomes were used as the antimicrobial nanomaterials in the study. They self-assembled into 700 nm sized structures with a zeta potential of -20 mV that were capable of killing oral bacteria (S. oralis growth inhibition time of 3.34 ± 0.52 h). In a phosphate (-ve) buffer the -ve α-TP liposomes did not penetrate multispecies oral biofilms, but in a Tris (hydroxymethyl)aminomethane (+ve) buffer they did (depth - 12.4 ± 3.6 µm). The Tris did not modify the surface charge of the α-TP nanomaterials, rather it facilitated the α-TP-biofilm interactions through electrolyte screening (Langmuir modelled surface pressure increase of 2.7 ± 1.8 mN/ m). This data indicated that EPS resistance was mediated through charge repulsion and that this effect could be diminished through the co-administration of cationic electrolytes.
Subject(s)
Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Electrolytes/chemistry , Nanostructures/chemistry , Streptococcus oralis/drug effects , alpha-Tocopherol/analogs & derivatives , Anti-Bacterial Agents/chemistry , Biofilms/growth & development , Buffers , Drug Resistance, Bacterial/drug effects , Extracellular Polymeric Substance Matrix/chemistry , Liposomes/chemistry , Particle Size , Permeability , Static Electricity , Streptococcus oralis/chemistry , Streptococcus oralis/growth & development , alpha-Tocopherol/chemistry , alpha-Tocopherol/pharmacologyABSTRACT
Among the viridans group streptococci, S. mitis-oralis strains are frequently resistant to multiple ß-lactams and tolerant to vancomycin (VAN). This scenario has led to the proposed clinical use of newer agents, like daptomycin (DAP) for such S. mitis-oralis strains. However, recent recognition of the rapid and durable emergence of high-level DAP-resistance (DAP-R; DAP MICs > 256 µg/ml) induced by DAP exposures in vitro and in vivo has dampened enthusiasm for such approaches. In this study, we evaluated a broad range of DAP combination regimens in vitro for their capacity to prevent emergence of high-level DAP-R in a prototype S. mitis-oralis strain (351) during serial passage experiments, including DAP + either gentamicin (GEN), rifampin (RIF), trimethoprim-sulfamethoxazole (TMP-SMX), imipenem (IMP), ceftaroline (CPT), tedizolid (TDZ), or linezolid (LDZ). In addition, we assessed selected DAP combination regimens for their ability to exert either an early bactericidal impact and/or synergistically kill the S. mitis-oralis study strain. During serial passage, three of the eight antibiotic combinations (DAP + GEN, CPT, or TMP- SMX) exhibited significantly reduced DAP MICs (≈ by 8-40 fold) vs serial exposure in DAP alone (DAP MICs > 256 µg/ml). In addition, combinations of DAP + GEN and DAP + CPT were both bactericidal and synergistic in early time-kill curve interactions.
Subject(s)
Anti-Bacterial Agents/pharmacology , Daptomycin/pharmacology , Streptococcus mitis/drug effects , Streptococcus oralis/drug effects , Cephalosporins/pharmacology , Drug Combinations , Drug Resistance, Bacterial , Gentamicins/pharmacology , Humans , Imipenem/pharmacology , Linezolid/pharmacology , Microbial Sensitivity Tests , Organophosphates/pharmacology , Oxazoles/pharmacology , Rifampin/pharmacology , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology , CeftarolineABSTRACT
'Soft' nanomaterials have the potential to produce substantive antibiofilm effects. The aim of this study was to understand the oral antimicrobial activity of soft nanomaterials generated from alpha-tocopherol (α-T) and alpha-tocopherol phosphate (α-TP). (+) α-TP formed planar bilayer islands (175 ± 21 nm, -14.9 ± 3.5 mV) in a Trizma® buffer, whereas (+) α-T formed spherical liposomes (563 ± 1 nm, -10.5 ± 0.2 mV). The (+) α-TP bilayers displayed superior Streptococcus oralis biofilm growth retardation, a more substantive action, generated a superior adsorption to hydroxyapatite and showed an enhanced inhibition of multi-species bacterial saliva biofilm growth (38 ± 7µm vs 58 ± 18 µm, P Ë 0.05) compared to (+) α-T. Atomic force microscopy data indicated that the ability of the 'soft' α-TP nanomaterials to transition into planar bilayer structures upon contact with interfaces facilitated their adhesive properties and substantive antimicrobial effects.
Subject(s)
Anti-Infective Agents/administration & dosage , Biofilms/drug effects , Lipid Bilayers/chemistry , Saliva/microbiology , Streptococcus mutans/drug effects , Streptococcus oralis/drug effects , alpha-Tocopherol/analogs & derivatives , Adhesives , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Biofilms/growth & development , Humans , Liposomes/administration & dosage , Liposomes/chemistry , Microscopy, Atomic Force , Mouth/microbiology , Streptococcus mutans/growth & development , Streptococcus oralis/growth & development , alpha-Tocopherol/chemistry , alpha-Tocopherol/pharmacologyABSTRACT
Titanium (Ti) implants have been commonly used in oral medicine. However, despite their widespread clinical application, these implants are susceptible to failure induced by microbial infection due to bacterial biofilm formation. Immobilization of chimeric peptides with antibacterial properties on the Ti surface may be a promising antimicrobial approach to inhibit biofilm formation. Here, chimeric peptides were designed by connecting three sequences (hBD-3-1/2/3) derived from human ß-defensin-3 (hBD-3) with Ti-binding peptide-l (TBP-l: RKLPDAGPMHTW) via a triple glycine (G) linker to modify Ti surfaces. Using X-ray photoelectron spectroscopy (XPS), the properties of individual domains of the chimeric peptides were evaluated for their binding activity toward the Ti surface. The antimicrobial and anti-biofilm efficacy of the peptides against initial settlers, Streptococcus oralis (S. oralis), Streptococcus gordonii (S. gordonii) and Streptococcus sanguinis (S. sanguinis), was evaluated with confocal laser scanning microscopy (CLSM) and scanning electron microscopy (SEM). Transmission electron microscopy (TEM) and real-time quantitative PCR (qRT-PCR) were used to study cell membrane changes and the underlying antimicrobial mechanism. Compared with the other two peptides, TBP-1-GGG-hBD3-3 presented stronger antibacterial activity and remained stable in saliva and serum. Therefore, it was chosen as the best candidate to modify Ti surfaces in this study. This peptide inhibited the growth of initial streptococci and biofilm formation on Ti surfaces with no cytotoxicity to MC3T3-E1 cells. Disruption of the integrity of bacterial membranes and decreased expression of adhesion protein genes from S. gordonii revealed aspects of the antibacterial mechanism of TBP-1-GGG-hBD3-3. We conclude that engineered chimeric peptides with antimicrobial activity provide a potential solution for inhibiting biofilm formation on Ti surfaces to reduce or prevent the occurrence of peri-implant diseases.